^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BP1200

    i
    Other names: BP1200
    Associations

    News

    Trials
    Company:
    BrightPath Biotherap
    Drug class:
    CD73 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    A novel therapeutic antibody against CD73 that ameliorates the tumor microenvironment and improves the efficacy of cancer immunotherapy (AACR 2022)
    The novel anti-human CD73 antibody, BP1200, ameliorates immunosuppressive TME caused by adenosine and enhances antitumor immune responses. The combination of BP1200 and immune-checkpoint inhibitors for cancer treatment will be a promising therapeutic option in clinical practice.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    NT5E (5'-Nucleotidase Ecto)
    |
    CD73 expression
    |
    BP1200